E-ISSN 2534-9821
 
2020, Vol: 4, Issue: 12
4/12Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles
Required files to be uploaded

Copyright Transfer Form

Case Report 


Fibroblast growth factor: A target for covid-19 infection

Pedro Cuevas, Antonio Manquillo, Pedro Guillen, Guillermo GIménez-Gallego.

Abstract
In the last few months, covid-19 has spread as a highly contagious pandemic. Currently no therapies have proven to be effective for the treatment of this severe illness that progresses with a strong inflammation in different organs and systems. Because fibroblast growth factor (FGF) is a potent inflammatory agent, we have tested, in one patient who didn’t respond to the protocol therapy, the effect of FGF inhibition with an anti-inflammatory and antiviral compound with a large history of medical use which was reported as the most effective anti-FGF inhibitor: dobesilate. After five days of oral treatment, dobesilate resulted in amelioration of chest radiographies as well as in clinical improvement, opening a new possible therapeutic mean to be tested in patients.

Key words: Covid-19 infection, fibroblast growth factor, dobesilate


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Pedro Cuevas
Articles by Antonio Manquillo
Articles by Pedro Guillen
Articles by Guillermo GIménez-Gallego
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego. Fibroblast growth factor: A target for covid-19 infection. Int J Med Rev Case Rep. 2020; 4(5): 122-125. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19

Web Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego. Fibroblast growth factor: A target for covid-19 infection. http://www.mdpub.net/?mno=103656 [Access: November 03, 2020]. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19

AMA (American Medical Association) Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego. Fibroblast growth factor: A target for covid-19 infection. Int J Med Rev Case Rep. 2020; 4(5): 122-125. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19


Vancouver/ICMJE Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego. Fibroblast growth factor: A target for covid-19 infection. Int J Med Rev Case Rep. (2020), [cited November 03, 2020]; 4(5): 122-125. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19


Harvard Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego (2020) Fibroblast growth factor: A target for covid-19 infection. Int J Med Rev Case Rep, 4 (5), 122-125. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19


Turabian Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego. 2020. Fibroblast growth factor: A target for covid-19 infection. International Journal of Medical Reviews and Case Reports, 4 (5), 122-125. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19


Chicago Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego. "Fibroblast growth factor: A target for covid-19 infection." International Journal of Medical Reviews and Case Reports 4 (2020), 122-125. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19


MLA (The Modern Language Association) Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego. "Fibroblast growth factor: A target for covid-19 infection." International Journal of Medical Reviews and Case Reports 4.5 (2020), 122-125. Print. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19


APA (American Psychological Association) Style

Pedro Cuevas| Antonio Manquillo| Pedro Guillen| Guillermo GIménez-Gallego (2020) Fibroblast growth factor: A target for covid-19 infection. International Journal of Medical Reviews and Case Reports, 4 (5), 122-125. doi:10.5455/IJMRCR.Fibroblast-growth-factor-COVID-19


Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights) Privacy Policy Publication Ethics and Publication Malpractice Statement Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information
Copyright © 2021 International Journal of Medical Reviews and Case Reports All Rights Reserved. Subject to change without notice from or liability to International Journal of Medical Reviews and Case Reports.
For best results, please use Internet Explorer or Google Chrome

Contact Information


Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31,  Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press. 

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.